New drugs with novel mechanisms of action are needed in the fight against cancer. Gene therapy provides great opportunities for developing new methods for improved cancer treatment. In this regard, a number of different viral and non-viral vectors have been studied in the search for the ideal cancer gene therapy drug. Since the eradication of smallpox, vaccinia virus (VACV) has been developed as a vector for vaccines against infectious diseases and immunotherapies for cancer, including oncolytic virotherapy. VACV has been studied for its use in cancer therapy mainly in three ways: 1) as a gene therapy vector for tumor specific delivery of therapeutic genes; 2) as a tumor selective replicating oncolytic virus and 3) as a cancer vaccine expressing tumor antigens and/or immunostimulatory molecules.
Figure 1. Vaccinia virus life cycle.
Among the poxviruses, VACV is one of the platforms boasting several features that meet requirements for oncolytic virotherapy:
QVirus™ Platform offers a comprehensive portfolio of oncolytic VACV services for the efficient design, development, manufacturing and analytical testing of virus vector products. So far, we have developed an efficient way to generate recombinant VACVs, including inserting and/or deleting GOI(s) in VACVs. We also provide customized oncolytic vaccinia virus and proof-of-concept validation study for the oncolytic virus.
Our QVirus™ Platform provides a one-step solution of oncolytic virus engineering. If you have any special requirements, please feel free to contact us.
1. Guse K, et al. Oncolytic vaccinia virus for the treatment of cancer. Expert Opinion on Biological Therapy, 2011, 11(5):595-608.
2. Dana H. Genetically Engineered Vaccinia Viruses As Agents for Cancer Treatment, Imaging, and Transgene Delivery. Frontiers in Oncology, 2017, 7:96-.
3. Guo Z S, et al. Vaccinia virus-mediated cancer immunotherapy: Cancer vaccines and oncolytics. 2019.